Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label Study of ONC201 in Adults With Recurrent High-grade Glioma

NCT03295396 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.

NCT NCT03295396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03295396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label Study of ONC201 in Adults With Recurrent High-grade Glioma
Lead sponsor
Jazz Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
October 30, 2017
Completion date
July 19, 2023
Enrollment
73 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

glioma